On October 3, 2019 Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, reported it has entered into an exclusive distribution agreement for its non-opioid metastatic cancer pallion drug, Strontium-89 Chloride Injection USP (Strontium-89)/Metastron, with Jubilant Radiopharma for the United States market (Press release, Q BioMed, OCT 3, 2019, View Source [SID1234540053]). Jubilant Radiopharma is an industry leading pharmaceutical company specializing in nuclear medicine focused on developing, manufacturing, commercializing and distributing high quality and sustainable diagnostic and therapeutic agents on a global scale.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Strontium-89 is an FDA-approved non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer. The product is administered intravenously once every three months as an alternative to opioid analgesics and plays a critical role in the treatment of metastatic bone pain.

The partnership between Q BioMed and Jubilant Radiopharma means that once the FDA approves the Q BioMed contract manufacturer, the large population of potential Strontium-89 patients in the United States will again have the opportunity to access the drug. Denis Corin, CEO of Q BioMed, said of the deal, "Our partnership with Jubilant Radiopharma is an essential component of our upcoming commercial launch and means that we’ll be able to reach providers and patients across the country through a scalable, highly-efficient program, thereby re-establishing supply of this life-changing therapy to those suffering from this debilitating pain."

Jubilant Radiopharma operates the second largest commercial radiopharmacy network in the United States. Pramod Yadav, CEO, Jubilant Pharma Limited stated, "Jubilant Radiopharma is committed to improving lives through Nuclear Medicine by providing healthcare professionals access to high quality, FDA approved products that enable better patient outcomes. We are pleased to partner with Q BioMed to bring this important cancer pain therapy to healthcare providers and patients who so desperately need choices in cancer pain treatment."

Q BioMed and Jubilant Radiopharma intend to announce further details regarding availability of Strontium-89 later this year.

On October 3, 2019 Ryvu Therapeutics, a clinical-stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, reported that two abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 34th Annual Meeting (SITC 2019) in National Harbor, MD from November 6 – 10, 2019 (Press release, Ryvu Therapeutics, OCT 3, 2019, View Source [SID1234540052]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstracts, which will be presented in a poster session, include leading immuno-oncology and immunometabolism programs developed by the company: novel, dual A2A/A2B antagonist and small molecule, direct STING agonists.

Details of the posters are as follows:

Poster 797: Novel dual A2A/A2B receptor antagonist reverses adenosine-mediated immune suppression – in vitro and in vivo characterization.
Category: Novel Single-Agent Immunotherapies

Poster 661: Development and characterization of next generation small molecule STING agonists
Category: Immune-stimulants and immune modulators

To view these abstracts, please visit the SITC (Free SITC Whitepaper) 2019 website located at View Source

Last week, Ryvu Therapeutics (formerly Selvita) published a poster on its leading A2A/A2B program at the CICON 2019 – Translating science into survival – Conference, which took place in Paris, France, September 25-28. Poster entitled "Characterization of novel potent dual A2A/A2B adenosine receptor antagonists for cancer immunotherapy" is now available at Ryvu corporate website: View Source

On October 3, 2019 BD (Becton, Dickinson and Company) (NYSE:BDX) reported that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year 2019 earnings conference call on Tuesday, November 5, 2019, at 8:00 a.m. (ET) (Press release, BD Pharmaceutical Systems, OCT 3, 2019, View Source [SID1234540051]). BD will issue a press release detailing the quarter’s earnings earlier that morning.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast of the conference call, along with related slides, will be accessible through BD’s website at www.bd.com/investors and will be available for replay through Tuesday, November 12, 2019.

On October 3, 2019 HCP, Inc. (NYSE: HCP) reported its third quarter 2019 financial results after the close of trading on the New York Stock Exchange on Wednesday, October 30, 2019 (Press release, Healthcare Property Investors (HCP), OCT 3, 2019, https://www.prnewswire.com/news-releases/hcp-to-report-third-quarter-2019-financial-results-and-host-conference-callwebcast-300929066.html [SID1234540050]). HCP will host a conference call and webcast on Thursday, October 31, 2019, at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time) in order to review its financial performance and operating results for the third quarter ended September 30, 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The dial-in number for the conference call is (888) 317-6003 (U.S.) or (412) 317-6061 (international). The conference ID number is 2983226. You may also access the conference call via webcast at www.hcpi.com under Investor Relations. An archive of the webcast will be available on HCP’s website through October 31, 2020, and a telephonic replay can be accessed through November 15, 2019, by calling (877) 344-7529 (U.S.) or (412) 317-0088 (international) and entering conference ID number 10135160.

On October 3, 2019 The Janssen Pharmaceutical Companies of Johnson & Johnson reported that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for niraparib, an orally-administered poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with BRCA1/2 gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have received prior taxane chemotherapy and androgen receptor (AR)-targeted therapy (Press release, Johnson & Johnson, OCT 3, 2019, View Source [SID1234540049]). A Breakthrough Therapy Designation is granted to expedite the development and regulatory review of an investigational medicine that is intended to treat a serious or life-threatening condition.1 The criteria for Breakthrough Therapy Designation require preliminary clinical evidence that demonstrates the drug may have substantial improvement on at least one clinically significant endpoint over available therapy.1

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BRCA1/2 mutations are the most common DNA-repair gene defects (DRD) in patients with mCRPC.2 Patients with a DRD in BRCA1/2 are at an elevated risk for both prostate cancer occurrence and more aggressive disease.2

"Niraparib is a PARP inhibitor that we believe may help address an important unmet need for patients with metastatic castration-resistant prostate cancer who have mutations in DNA-repair genes," said Kiran Patel, M.D., Vice President, Clinical Development, Solid Tumors, Janssen Research & Development, LLC. "We are pleased with the FDA’s Breakthrough Therapy Designation as we continue the clinical development of niraparib, and we look forward to working with the agency in our continued focus and commitment to bring new advancements to patients diagnosed with prostate cancer."

The Breakthrough Therapy Designation is based on data from the GALAHAD study, a Phase 2, multicenter, open-label clinical trial evaluating the efficacy and safety of niraparib in the treatment of adult patients with mCRPC and DRD who had received treatment with next-generation androgen-receptor targeting therapies and docetaxel.3 Data from the Phase 2 GALAHAD study were recently presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) 2019 Annual Congress as a late-breaking abstract.

About Metastatic Castration-Resistant Prostate Cancer
Metastatic castration-resistant prostate cancer is a form of prostate cancer that has spread to other parts of the body and keeps growing even when the amount of testosterone in the body is reduced to very low levels.4,5 The most common metastatic sites are bones, followed by distant lymph nodes, liver and thorax.6 Prostate cancer is the second most common type of cancer in men worldwide.7 More than one million people around the world are diagnosed with prostate cancer each year.7,8

Other Ongoing Studies with Niraparib
Ongoing studies for niraparib include the Phase 3 MAGNITUDE study evaluating niraparib in combination with ZYTIGA (abiraterone acetate) and prednisone in adults with metastatic prostate cancer. The MAGNITUDE study is evaluating niraparib plus ZYTIGA and prednisone in a broader population than GALAHAD in patients with frontline mCRPC disease. In addition, QUEST, a Phase 1b/2 study of niraparib combination therapies for the treatment of mCRPC, is ongoing.

About Niraparib
Niraparib is an orally-administered selective PARP inhibitor that is currently being studied by Janssen for the treatment of patients with prostate cancer. In April 2016, Janssen entered a worldwide (except Japan) collaboration and license agreement with TESARO, Inc., for exclusive rights to niraparib in prostate cancer. In the U.S., niraparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.9 Niraparib is currently marketed as ZEJULA by TESARO, an oncology-focused business within GSK, devoted to providing transformative therapies to people facing cancer. Please refer to the full Prescribing Information available at View Source